医学
心肌炎
房室传导阻滞
心脏毒性
心脏传导阻滞
内科学
心脏病学
心电图
永久起搏器
化疗
作者
Dongmei Xie,Ting Yan,Xin Zhang,Xingbin Liu
摘要
ABSTRACT Immune checkpoint inhibitor (ICI) has demonstrated promising results in treating various cancers, but its associated cardiotoxicity, especially ICI‐associated myocarditis, presents a serious concern. We reported a case of a 63‐year‐old male who complained of progressive dyspnea after tislelizumab, a novel humanized anti‐PD‐1 monoclonal antibody, for hepatocellular carcinoma. Upon diagnosing ICI‐related myocarditis, corticosteroid therapy was initiated immediately. The elevated biomarkers quickly decreased, but the atrioventricular block progressed from first‐degree to third‐degree, necessitating pacemaker implantation. This is the first report of complete AVB consecutive to tislelizumab‐induced myocarditis, highlighting the importance of early corticosteroid therapy and continuous electrocardiography monitoring.
科研通智能强力驱动
Strongly Powered by AbleSci AI